Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?

Paola Papaldo, Serena Di Cosimo, Gianluigi Ferretti, Paolo Carlini, Alessandra Fabi, Fabiana Cecere, Francesco Cognetti

Research output: Contribution to journalArticlepeer-review

Abstract

Recent evidence suggests that young women with estrogen receptor (ER)-positive breast cancer (BC) require additional treatment because of the inadequacy of cyclophosphamide, methotrexate fluorouracil (CMF) alone. Herein we report our findings from 368 premenopausal patients given adjuvant anthracycline alone. Overall, patients had a significantly increasing risk of relapse and dying with decreasing age at diagnosis and ER-negative disease. Interestingly, ER expression was not a negative prognostic factor, even among women

Original languageEnglish
Pages (from-to)269-272
Number of pages4
JournalBreast
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 2006

Keywords

  • Breast cancer
  • Estrogen receptor status
  • Prognosis
  • Young women

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?'. Together they form a unique fingerprint.

Cite this